Author/Editor		Grašič-Kuhar, Cvetka; Ložar, Taja; Bešić, Nikola; Marolt-Mušič, Maja
Title		Outcome of patients with locally advanced metastatic medullary thyroid cancer and induction therapy with tyrosine kinase inhibitors in Slovenia
Type		članek
Vol. and No.		, št. Vol. 38
Publication year		2021
Volume		str. 5684‐5699
ISSN		0741-238X - Advances in therapy
Language		eng
Abstract		The aim of our retrospective study was to evaluate the outcome of patients with metastatic medullary thyroid cancer (MTC) treated with tyrosine kinase inhibitors (TKIs) and/or chemotherapy with the emphasis on analysis on the cohort treated by induction TKI because of locally advanced metastatic MTC. Methods We analyzed the outcome of 30 patients (21 males, 9 females; median age 63.8 years) with metastatic MTC treated between 2000%2020. Sunitinib was used in 20 patients. Results Median progression-free survival on TKI and on chemotherapy was 10.6 (95% CI 7.1%14) months and 3.5 (95% CI 1.4%5.5) months, respectively. Median overall survival from diagnosis and from metastasis presentation was 38.2 (95% CI 4.7%71.7) months and 20.9 (95% CI 13.8%27.9) months, respectively. Eight patients (five females, three males; 58%86 years of age, median age 70 years) were treated with induction TKI because of inoperable locally advanced and metastatic MTC. The response rate to induction TKI was 50%; two patients (25%) had stable disease, and two patients (25%) had progressive disease. Conclusion Our data support a new paradigm that TKIs may be the first treatment option in selected patients with locally advanced metastatic MTC, followed by locoregional treatment with surgery and/or external beam radiotherapy. Further studies are required to consolidate the presented data.
Keywords		rak ščitnice lokalno napredovali medularni rak kemoterapija thyroid cancer locally advanced metastatic medullary cancer chemotherapy